



Immedica and Innovative Medicines Group enter agreement on Loargys® (pegzilarginase) in Latin America

Stockholm, Sweden, October 1, 2025 – Immedica has entered into an agreement with Innovative Medicines Group giving Innovative Medicines the exclusive rights to Loargys® (pegzilarginase) in selected countries in Latin America*.

“We are very pleased to announce this new partnership with Innovative Medicines, which will enable patients with ARG1-D in Latin America to access Loargys. The agreement also further strengthens Immedica’s geographical footprint by introducing Loargys in this important region through a strong partner,” says Anders Edvell, CEO of Immedica.

*Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Mexico, Peru, Paraguay and Uruguay.

About Loargys®

Loargys (pegzilarginase) is a novel recombinant human enzyme and has been shown to rapidly and sustainably lower levels of the amino acid arginine and its toxic metabolites in plasma accompanied by improvements in clinical outcomes. It is the first and only disease-modifying treatment.

About ARG1-D

ARG1-D is one of the eight urea cycle disorder (UCD) subtypes. It shares overlapping features with other UCDs and the most prominent is the impairment in excreting nitrogen. However, in ARG1-D, hyperammonemia is generally less severe and instead these patients show spasticity, which other subtypes do not. The principal defect in ARG1-D leads to accumulation of plasma arginine and its toxic metabolites, which occurs in almost all patients with this disorder. Patients are often diagnosed in late infancy or early childhood and the symptoms include spasticity, seizures, developmental delay, intellectual disability, and early mortality.

About Innovative Medicines

Innovative Medicines is a pharmaceutical company focused on rare and specialty diseases in Latin America. The company is dedicated to improving the lives of patients and their families by ensuring access to innovative therapies. Through strong regional presence and partnerships with leading global biotech and pharmaceutical companies, Innovative Medicines brings novel treatments to patients across Latin America who suffer from rare and high-burden diseases.

About Immedica

Immedica is a pharmaceutical company, headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Immedica’s capabilities cover marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory, medical affairs and market access, as well as a global distribution network serving patients in more than 50 countries. Immedica is fully dedicated to helping those living with diseases which have a large unmet medical need. Immedica’s therapeutic areas are within RARE metabolic, RARE hematology & oncology, RARE neurology and specialty care. Immedica was founded in 2018 and employs today around 150 people across Europe, the Middle East and the United States. Immedica is backed by the investment firms KKR and Impilo.

For more information visit www.immedica.com.

Immedica contact:

Linda Holmström

VP, Head of HR & Communication

linda.holmstrom@immedica.com

Immedica Pharma AB

Solnavägen 3H

SE-113 63 Stockholm